Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam says Chief Legal Officer Indrani Franchini leaves March 1, 2024, stays as consultant

Neutral Impact 3 of 5 leadership Written later

Alnylam Pharmaceuticals said its Executive Vice President, Chief Legal Officer and Secretary, Indrani L. Franchini, stepped down from that role effective March 1, 2024, as previously reported in January. Under a separation agreement, she receives severance of $597,000 and other benefits, and will provide consulting services through March 1, 2025.

Key points

  • Separation date: March 1, 2024; Franchini was Executive Vice President, Chief Legal Officer and Secretary.
  • Severance totals $597,000, paid as twelve months of base salary in bi-weekly installments, plus a 2023 annual incentive payment adjusted by the Board's corporate multiplier.
  • Consulting period runs until March 1, 2025; hours above ten per month are paid at $500 per hour, and unvested equity awards continue to vest.

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECMar 4, 2024, 4:33 PM ET
Accession number0001193125-24-057906

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.